The Limits of Equilibrium Affinity as a Predictive Tool

For decades, the equilibrium dissociation constant—Kd—has functioned as the lingua franca of peptide-receptor pharmacology. A lower Kd signals tighter binding, and tighter binding has conventionally been equated with greater potency. The logic is intuitive, but it is incomplete.

Kd is defined as the ratio of the dissociation rate constant to the association rate constant: Kd = koff / kon. Two peptides can therefore share an identical Kd while differing dramatically in their individual rate constants. One peptide might associate slowly and dissociate slowly; another might associate rapidly and dissociate rapidly. At equilibrium, their receptor occupancy appears equivalent. In a living system, where receptor exposure is time-limited and downstream signaling unfolds over minutes to hours, the kinetic profiles diverge in ways that equilibrium measurements cannot capture [1].

This distinction is not merely academic. Preclinical models have repeatedly demonstrated that peptides with comparable Kd values produce measurably different pharmacodynamic profiles when their kinetic parameters differ. Understanding why requires a brief examination of what kon and koff actually represent at the molecular level.

Association and Dissociation: A Mechanistic Primer

The association rate constant (kon) describes how rapidly a peptide collides with and forms a stable complex at its receptor. It is expressed in units of M⁻¹s⁻¹ and is partly governed by diffusion, molecular geometry, and the electrostatic complementarity between ligand and binding site. For peptide ligands, kon values typically fall in the range of 10⁴ to 10⁷ M⁻¹s⁻¹, with values at the upper end approaching the diffusion limit [1].

The dissociation rate constant (koff) describes how rapidly the bound complex falls apart. It carries units of s⁻¹ and has a direct, intuitive interpretation: the half-life of the peptide-receptor complex is approximately 0.693 / koff. A peptide with a koff of 10⁻¹ s⁻¹ has a complex half-life of roughly seven seconds. A peptide with a koff of 10⁻³ s⁻¹ has a complex half-life of approximately 693 seconds—nearly twelve minutes. That difference of two orders of magnitude in koff produces a hundred-fold difference in receptor residency time, yet if kon scales proportionally, both peptides may present the same Kd to an equilibrium binding assay.

Receptor residency time—the average duration a ligand remains bound—has emerged as a pharmacologically meaningful parameter in its own right [2]. Extended residency can sustain receptor activation beyond the period of free ligand availability, effectively decoupling the duration of pharmacological effect from plasma half-life.

Functional Selectivity and the Kinetic Dimension

Functional selectivity, sometimes called biased agonism, describes the phenomenon whereby structurally distinct ligands acting at the same receptor preferentially activate different intracellular signaling pathways. A receptor coupled to both G-protein and β-arrestin cascades may be engaged by one ligand primarily through G-protein signaling and by another primarily through arrestin-mediated internalization, even when both ligands bind the same orthosteric site [2].

Kinetic parameters contribute to functional selectivity through a mechanism sometimes termed kinetic selectivity. The conformational state of a receptor is not static; it fluctuates among multiple active and inactive configurations. A peptide with a slow off-rate stabilizes whichever receptor conformation it encounters for longer, effectively locking the receptor into a particular signaling-competent state. A peptide with a rapid off-rate samples multiple conformations more transiently, potentially engaging a different ensemble of downstream effectors [2].

This means that two peptides with similar equilibrium affinities for a receptor can produce qualitatively different physiological outcomes not because they bind different sites, but because their kinetic profiles favour different receptor conformations and therefore different signalling cascades. Identifying this divergence requires kinetic measurement; equilibrium assays are blind to it.

Real-Time Measurement Techniques

Surface Plasmon Resonance

Surface plasmon resonance (SPR) is the most widely adopted label-free technique for measuring peptide-receptor binding kinetics in real time. In a typical SPR experiment, the receptor or a receptor fragment is immobilized on a sensor chip. Peptide analyte flows across the surface, and changes in refractive index near the chip surface—caused by mass accumulation during association and mass loss during dissociation—are recorded as a sensorgram [1].

Fitting the association and dissociation phases of the sensorgram to appropriate kinetic models yields kon and koff directly. The ratio koff / kon then provides a kinetically derived Kd that can be compared against equilibrium measurements for internal validation. SPR is particularly well suited to peptides because the technique operates across a broad analyte mass range and can resolve fast kinetics with appropriate flow cell design.

A practical limitation is that receptor immobilization can alter native conformation, particularly for multi-pass transmembrane receptors such as GPCRs. Detergent-solubilized receptor preparations or lipid nanodisc formats partially mitigate this concern, though neither fully replicates the membrane environment of an intact cell [1].

Biolayer Interferometry

Biolayer interferometry (BLI) operates on a related optical principle. A fiber-optic biosensor tip coated with the receptor is dipped alternately into peptide solution and buffer, and interference patterns in reflected white light report on mass changes at the tip surface. BLI is performed in standard microplate wells without microfluidics, making it more accessible and higher-throughput than SPR for initial kinetic screening [4].

BLI sensorgrams yield the same kon and koff parameters as SPR, though the technique is generally considered less sensitive at very low analyte concentrations. For peptide characterization, where analyte concentrations can typically be prepared at nanomolar to micromolar levels without difficulty, BLI offers a practical and reproducible kinetic profiling platform [4].

Stopped-Flow Fluorescence

Stopped-flow fluorescence techniques are particularly useful when rapid kinetics—association half-lives of milliseconds to seconds—exceed the time resolution of SPR or BLI. In stopped-flow experiments, fluorescently labelled peptide and receptor solutions are mixed within milliseconds, and fluorescence changes reporting on complex formation are recorded in real time. The technique operates in solution rather than at a surface, avoiding immobilization artifacts entirely, though it requires fluorescent labelling that may perturb native binding behaviour.

GLP-1 Receptor Agonists as a Kinetic Case Study

The glucagon-like peptide-1 (GLP-1) receptor agonist class provides an instructive illustration of how kinetic parameters correlate with pharmacological duration in a well-characterised peptide system. Exenatide and liraglutide are both approved GLP-1 receptor agonists with documented clinical utility in type 2 diabetes management, and their kinetic profiles differ in ways that illuminate broader principles [3].

Exenatide is a 39-amino acid peptide derived from exendin-4, a salivary peptide from the Gila monster. Liraglutide is a fatty-acid-acylated analogue of human GLP-1(7-37) designed for extended plasma half-life through albumin binding. Comparative binding studies have demonstrated that liraglutide exhibits a markedly slower dissociation rate from the GLP-1 receptor than exenatide, contributing to prolonged receptor occupancy that persists beyond the period of peak plasma concentration [3].

This kinetic difference does not manifest as a proportionally lower Kd—the equilibrium affinities of the two compounds are broadly comparable in cell-based assays. What differs is the temporal profile of receptor engagement. The slower koff of liraglutide extends receptor residency, which preclinical data indicates contributes to its once-daily dosing profile compared with the twice-daily administration of the original exenatide formulation [3]. This example demonstrates that kinetic parameters can carry direct translational implications even within a class of compounds sharing a common mechanism.

It is important to note that both compounds are approved medicines, and the kinetic differences described here are referenced from their documented pharmacological characterisation rather than from investigational contexts.

Connecting Kinetics to In Vivo Pharmacodynamics

The translation of in vitro kinetic parameters to in vivo receptor occupancy predictions requires pharmacokinetic-pharmacodynamic (PK-PD) modelling. Receptor occupancy at any moment is determined not only by the intrinsic koff of the peptide-receptor complex but also by the free peptide concentration at the receptor site, which is itself a function of absorption, distribution, metabolism, and elimination [5].

Kinetic binding models can be integrated with PK profiles to generate receptor occupancy-time curves. When the peptide concentration falls below a threshold during the elimination phase, the rate of receptor dissociation relative to re-association shifts, and occupancy declines. A peptide with a slow koff maintains occupancy longer during this elimination phase, effectively extending the pharmacodynamic response beyond what plasma concentration alone would predict [5].

This modelling approach has practical value in compound selection. Given two peptides with similar PK profiles and similar Kd values, the one with a slower koff is predicted to maintain receptor occupancy longer during the trough of the dosing interval. Kinetic profiling therefore provides a rational basis for prioritising candidates before committing to resource-intensive in vivo efficacy studies.

Limitations and Interpretive Cautions

Kinetic measurements carry several important caveats that responsible interpretation requires acknowledging.

Temperature sensitivity is significant. Kinetic rate constants, particularly koff, are strongly temperature-dependent. Measurements conducted at ambient temperature (25°C) may not accurately reflect rate constants at physiological temperature (37°C). Reporting temperature alongside kinetic data is essential, and extrapolation across temperature conditions should be approached with caution [1].

Membrane orientation artifacts affect surface-based techniques when transmembrane receptors are immobilised. Detergent solubilisation and chip coupling chemistry can alter receptor conformation, expose cryptic binding sites, or restrict conformational flexibility that is central to receptor function. Kinetic parameters derived from immobilised receptor fragments may not accurately represent those at the intact cell surface.

Rebinding effects can artificially slow the apparent koff in SPR experiments when high receptor density on the sensor surface allows dissociated peptide to re-associate before diffusing away from the surface. Careful experimental design—including low receptor surface densities and appropriate flow rates—is necessary to obtain accurate koff measurements.

Cell-free to intact tissue translation remains an unresolved challenge. Receptor-associated proteins, membrane lipid composition, receptor oligomerisation, and endogenous allosteric modulators all influence kinetic parameters in native tissue in ways that cell-free or heterologous expression systems cannot fully replicate. Kinetic data from purified systems should therefore be treated as a predictive tool rather than a definitive characterisation of in vivo behaviour.

Practical Guidance for Interpreting Kinetic Data

For researchers encountering kinetic binding data in the literature or in compound characterisation reports, several interpretive principles are worth internalising.

A slow koff—below approximately 10⁻³ s⁻¹, corresponding to a complex half-life exceeding ten minutes—suggests that receptor occupancy will be sustained well beyond the period of peak free peptide concentration. This is pharmacologically advantageous when prolonged receptor activation is the objective, but it may also complicate washout and limit the ability to reverse pharmacological effects rapidly.

A fast kon—above approximately 10⁶ M⁻¹s⁻¹—indicates that the peptide will achieve substantial receptor occupancy rapidly after administration, even at relatively low concentrations. This can be advantageous for acute pharmacological applications but provides less differentiation in sustained-release contexts.

When comparing two peptides with similar Kd values, the one with the slower koff is generally predicted to produce more sustained receptor activation in vivo, all else being equal. When comparing two peptides with similar koff values, the one with the faster kon will achieve equivalent occupancy at lower concentrations.

Kinetic selectivity across receptor subtypes—where a peptide dissociates slowly from a target receptor but rapidly from off-target receptors—can confer functional specificity that equilibrium affinity ratios alone underestimate [7]. Profiling kinetics across a receptor panel rather than at a single target therefore provides a more complete picture of selectivity.

Conclusion

Equilibrium binding affinity remains a necessary parameter in peptide pharmacology, but it is not sufficient. The individual rate constants that determine Kd—kon and koff—carry independent pharmacological information about how rapidly a peptide engages its receptor, how long it remains bound, and which signalling pathways that sustained engagement preferentially activates.

Real-time kinetic measurement techniques, including SPR, BLI, and stopped-flow fluorescence, have matured to the point where kinetic profiling is feasible as a routine component of preclinical characterisation. The GLP-1 receptor agonist class demonstrates, in an approved clinical context, that kinetic differences between structurally related peptides translate into meaningful differences in pharmacodynamic duration.

Kinetic data does not replace animal efficacy studies. Temperature artifacts, membrane orientation effects, and the complexity of intact tissue environments all limit the fidelity of cell-free kinetic measurements. What kinetic profiling provides is a mechanistically grounded intermediate layer of information—more predictive than equilibrium affinity alone, less resource-intensive than in vivo experimentation—that can sharpen compound selection decisions and deepen the mechanistic understanding of peptide pharmacology.